Poster Session B
Wednesday, May 18, 2016
5:00 p.m.–7:30 p.m.
Metropolitan Ballroom 2–4

B01 Integrated genomic analysis identifies two subsets of cervical cancer with potentially distinct therapeutic profiles. Carolyn Banister, University of South Carolina, College of Pharmacy, Columbia, SC, United States.

B02 Systematic identification of gene targets in a biobank of patient-derived glioblastoma cells. Sathishkumar Baskaran, Department of IGP, Uppsala University, Uppsala, Sweden.

B03 Development of retroviral replicating vectors expressing codon-optimized nitroreductase for prodrug activator gene therapy in human glioma models. Sara Collins, University of Miami, Miami, FL, United States.

B04 Synthetic lethal targeting of E-cadherin-deficient cancers. Parry Guilford, University of Otago, Dunedin, New Zealand.

B05 Identification and validation of TP53-dependent responses to cancer therapeutics. Changlong Liu, Department of Drug Discovery and Biomedical Sciences, The University of South Carolina, Columbia, SC, United States.

B06 Combined HDAC and mTOR inhibition exploits proteotoxic and oxidative cancer cell stress to drive tumor regression. Clare Malone, Brigham and Women's Hospital, Boston, MA, United States.

B07 Differential roles for AKT isoforms in BRAF mutant melanoma. Siobhan McRee, Tufts University, Boston, MA, United States.

B08 Blocking the stress specific APIM-PCNA interactions increases the efficacy of cancer therapies. Marit Otterlei, Norwegian University of Science and Technology, Trondheim, Norway.

B09 Diversity of resistance mechanisms to neoadjuvant androgen deprivation in high risk prostate cancer: A case for precision adjuvant therapy. Adam Sowalsky, National Cancer Institute, Bethesda, MD, United States.

B10 Synthetic lethal screen to identify novel therapies targeting TP53-mutant colon cancer cells. Charles Weige, Department of Drug Discovery and Biomedical Sciences, The University of South Carolina, Columbia, SC, United States.

B11 HER2 regulates PARP-1 expression via the let-7a microRNA in HER2+ breast cancer. Monicka Wielgos, University of Alabama at Birmingham, Birmingham, AL, United States.
B12 HSP90 inhibitor inhibit the activation of multiple kinase pathways and migration of pancreatic cancer cells. Masahiro Yamamura, Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Okayama, Japan.

B13 Reprogramming Glioblastoma Multiforme cells to neurons by protein kinase inhibitors. Qin Yang, Washington University, St. Louis, MO, United States.

B14 Neoantigen burden associates with chemoresponse in muscle-invasive bladder cancer patients receiving neoadjuvant chemotherapy. Philip Abbosh, Fox Chase Cancer Center, Philadelphia, PA, United States.

B15 Genome editing or shRNA knockdown of HPRT in hematopoietic stem cells enables combined preconditioning and in vivo chemoselection with 6-thioguanine. Katrin Hacke, University of Miami, Miami, FL, United States.

B16 Expression of programmed cell death ligand 1/2 and BCG immunotherapy in bladder cancer. Kyung Seok Han, Seoul National University Bundang Hospital, Seongnam, Korea, Republic Of.

B17, PR03 Molecular characterization of in vitro exhausted T cells. William Hastings, Novartis Institute for Biomedical Research, Cambridge, MA, United States.

B18 Development of human STING agonists for prostate cancer immunotherapy. Jian Hui Wu, McGill University, Montreal, QC, Canada.

B19 Targeting dependencies within apoptotic pathways through inhibition of BET bromodomains. Andrew Conery, Constellation Pharmaceuticals, Inc., Cambridge, MA, United States.

B20 Targeting androgen receptor and vitamin D receptor in triple negative breast cancers. Ankita Thakkar, University of Miami, Miami, FL, United States.


B22 Novel dual regulation of epithelial-mesenchymal transition and anoikis resistance prevents metastases of triple negative breast cancer. Koichi Ito, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

B23 Crucial deubiquitinases in cancer cell survival. Lorna Kategaya, Genentech, South San Francisco, CA, United States.

B24 Regulation of mutant p53 stability by the mevalonate pathway-Hsp40-CHIP axis. Alejandro Parrales, Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS, United States.

B26 Long interspersed nuclear element-1 regulates malignant transformation of lung bronchial epithelial cells through epithelial-to-mesenchymal transition. Ivan Aispuro, University of Arizona, Tucson, AZ, United States.
**Poster Session B**
Wednesday, May 18, 2016
5:00 p.m.–7:30 p.m.
Metropolitan Ballroom 2–4

B27 Assessment of chemotherapeutic responses to neoadjuvant FOLFOX and Aspirin on BIRC7 in colorectal adenocarcinoma cells induced in Albino rats. Mohammed Faruk, Ahmadu Bello University/Ahmadu Bello University Teaching Hospital, Zaria, Kaduna State, Nigeria.

B28 Induced expression of Sprouty4 in breast invasive ductal carcinoma cells inhibits ERK MAP kinase and reduces malignant phenotype. Ryan Jackson, Wayne State University, Detroit, MI, United States.

B29 Astrocytes activated in the periphery of glioma by tumoral RANKL promote glioma cell invasion through cytokine signaling. Jun-Kyum Kim, Korea University, Seoul, Korea, Republic Of.

B30 Inhibition of eIF4E/MNK axis by novel MNKDAs reduces breast cancer tumor growth, migration, invasion and metastasis. Senthilmurugan Ramalingam, University of Maryland Baltimore, Baltimore, MD, United States.


B32 The tumor-suppressor function of Erbin in colon cancer. Payton Stevens, University of Kentucky, Lexington, KY, United States.

B33 Persistent activation of ERK and SMAD4 nuclear retention by high free fatty acids promote breast cancer metastasis. Yong Wu, Charles Drew University of Medicine and Science, Los Angeles, CA, United States.

B34 CXCL10 suppresses tumor angiogenesis and impedes expression of critical angiogenic factors in renal cell carcinoma. Kyung Seok Han, Seoul National University Bundang Hospital, Seongnam, Korea, Republic Of.

B35, PR01 IACS-010759 a novel inhibitor of oxidative phosphorylation advancing into first-in-human studies to exploit metabolic vulnerabilities. Phillip Jones, MD Anderson Cancer Center, Houston, TX, United States.

B36 Compassionate use of an oncolytic adenovirus in a Stage IV treatment-refractory ovarian cancer patient. Katharina Feister, University of Miami, Miami, FL, United States.

B37 Topoisomerase II-targeting novel intervention: “Jekyll” physiology and “Hyde” pathology. Tsai-Kun Li, National Taiwan University College of Medicine, Taipei, Taiwan.

B38 IKKβ is a potential anti-angiogenic therapeutic target in KRAS-induced lung cancer. Daniela Bassères, University of São Paulo, São Paulo, Brazil.

B39 Genomic copy number alterations introduce a gene-independent viability bias in CRISPR-Cas9 knock-out screens of cancer cell lines. Robin Meyers, Broad Institute, Cambridge, MA, United States.
Poster Session B
Wednesday, May 18, 2016
5:00 p.m.–7:30 p.m.
Metropolitan Ballroom 2–4

B41 Statins show synthetic lethality in E-cadherin-deficient cells and are synergistic with SRC and HDAC inhibitors. Andrew Single, University of Otago, Dunedin, New Zealand.

B42 Live Tumor Culture Core (LTCC): Cell lines in the business of revealing cancer secrets. Aurea Sousa, University of Miami, Miami, FL, United States.

B43, PR02 Towards a Cancer Dependency Map. Aviad Tsherniak, Broad Institute of MIT and Harvard, Cambridge, MA, United States.

B44 Emerging targets from Cancer Dependency Map v0.1. Francisca Vazquez, Broad Institute, Cambridge, MA, United States.